长江生命科技(00775.HK) 公布,旗下针对滋养层细胞表面抗原2(TROP2)的新型癌症疫苗,在临床前阶段实验室测试中取得良好的早期成果。据介绍,TROP2乃一种在多类癌症中有过度表现的细胞表面糖蛋白,常见于乳癌、肺癌、胰脏癌及结直肠癌。由于此蛋白在癌细胞之高度表现及在正常组织中极少存在,TROP2遂成为肿瘤学中具发展潜力的治疗性标靶。长江生命科技表示,已向香港知识产权署提交circRNA及...
Source Link长江生命科技(00775.HK) 公布,旗下针对滋养层细胞表面抗原2(TROP2)的新型癌症疫苗,在临床前阶段实验室测试中取得良好的早期成果。据介绍,TROP2乃一种在多类癌症中有过度表现的细胞表面糖蛋白,常见于乳癌、肺癌、胰脏癌及结直肠癌。由于此蛋白在癌细胞之高度表现及在正常组织中极少存在,TROP2遂成为肿瘤学中具发展潜力的治疗性标靶。长江生命科技表示,已向香港知识产权署提交circRNA及...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.